Sonova AG
Stäfa, 8712, Switzerland
NCT Number: NCT04496271
Phonak Hearing Devices pass through different development and study phases. At an early stage, feasibility studies are conducted to investigate new algorithms, features and functions in an isolated manner. If the benefit is proven, their performance is then investigated regarding interdependency between all available algorithms, features and functions running in parallel in a hearing aid (pivotal/pre-validation studies) and, resulting from the pre-validation studies, they get optimized. Prior to product launch, the Phonak Hearing Systems get reviewed by a final quality control in terms of clinical trials. This is a validation study, investigating improved algorithms, features, functions and wearing comfort. This will be a clinical investigation which will be conducted mono centric at Sonova AG Headquarters based in Stäfa (Switzerland).
Looking for future studies?
Notify Me50 year and older
All sexes
Interventional
Not applicable
Stäfa, 8712, Switzerland
This study will investigate the combination of the features to determine if the audiological performance and quality of the new successor of the Marvel family shows an improved benefit over Phonak Audéo Marvel before going into the System Validation. Therefore this study will be a comparative study. The study will determine if hearing impaired users wearing the successor hearing aids, have better initial acceptance with the new precalculation, better sound quality and speech intelligibility, more clarity and loudness comfort in soft and loud environments compared to Phonak Marvel RIC (Receiver in channel) hearing aids. Another objective of the study is to compare the listening effort with the two different study devices.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
HI is developed to support hearing impaired people in calm and complex situations and to be able to participate in communication
Time frame: 5 weeks
Subjective rating of the overall satisfaction for sound quality by questionnaires for the new HI and the old comparative HI (%). The questionnaire includes rating scales for the satisfaction. The participant has to rate it in percentage (100% = very satisfy, 0% = very unsatisfy)
Time frame: 5 weeks
Evaluating subjectively the HI regarding to the naturalness of the own voice. Participant will be ask in the first visit for spontaneous acceptance, regarding to the quality of their own voice, by rating scales. They have to rate the clarity, dullness etc. of their own voice. Also they will be ask after the hometrial how satisfy they are with the sound quality of their own voice.They have to rate it by rating scales in percentage. (e.g. very satisfy = 100%, very unsatisfy = 0%)
Time frame: 5 weeks
Evaluating listening effort by a special feature. The participants will be in a noisy test situation and have to listen to words, which they should repeat. After each group of words they will be ask to rate how difficult it was to understand by a rating scala (very difficult-difficult-somewhat-easy-very easy). The participants have to do that with the new and the old RIC device. The test will be randomized and single blinded.
Sonova AG
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05219474
Ear Diseases, Hearing Disorders
New York, United States
View Trial DetailsNCT01805167
Ear Diseases, Hearing Disorders
Nice, France
View Trial DetailsNCT05070429
Aging, Ear Diseases
Hagerstown, Maryland, United States
View Trial DetailsNCT07501312
Ear Diseases, Hearing Disorders
Aurora, Illinois, United States
View Trial Details